(Q39385032)

11 September 2017

title

In vitro and in vivo anti-tumor activities of anti-EGFR single-chain variable fragment fused with recombinant gelonin toxin (English)

1 reference

11 September 2017

Xikun Zhou

1

1 reference

11 September 2017

Ji Qiu

2

1 reference

11 September 2017

Zhen Wang

3

1 reference

11 September 2017

Nongyu Huang

4

1 reference

11 September 2017

Xiaolei Li

5

1 reference

11 September 2017

Qian Li

6

1 reference

11 September 2017

Yinbing Zhang

7

1 reference

11 September 2017

Chengjian Zhao

8

1 reference

11 September 2017

Can Luo

9

1 reference

11 September 2017

Nannan Zhang

10

1 reference

11 September 2017

Xiu Teng

11

1 reference

11 September 2017

Zhongwen Chen

12

1 reference

11 September 2017

Xiao Liu

13

1 reference

11 September 2017

Xianlian Yu

14

1 reference

11 September 2017

Wenling Wu

15

1 reference

11 September 2017

Yu-quan Wei

16

1 reference

11 September 2017

Jiong Li

17

1 reference

11 September 2017

publication date

7 March 2012

1 reference

Journal of Cancer Research and Clinical Oncology

11 September 2017

published in

1 reference

11 September 2017

volume

138

1 reference

11 September 2017

issue

7

1 reference

11 September 2017

page(s)

1081-1090

1 reference

https://scigraph.springernature.com/pub.10.1007/s00432-012-1181-7

11 September 2017

exact match

0 references

cites work

Ligand-targeted therapeutics in anticancer therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1181-7

Phase II study of paclitaxel, carboplatin, and cetuximab as first line treatment, for patients with advanced non-small cell lung cancer (NSCLC): results of OPN-017.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1181-7

Therapeutic antibodies for human diseases at the dawn of the twenty-first century

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1181-7

Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1181-7

Clinical experience with anti-EGFR therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1181-7

Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1181-7

Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1181-7

Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1181-7

T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1181-7

Antitumor activity of fibroblast growth factor receptor 3-specific immunotoxins in a xenograft mouse model of bladder carcinoma is mediated by apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1181-7

The epidermal growth factor receptor as a target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1181-7

The vascular-targeting fusion toxin VEGF121/rGel inhibits the growth of orthotopic human bladder carcinoma tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1181-7

The growth factor fusion construct containing B-lymphocyte stimulator (BLyS) and the toxin rGel induces apoptosis specifically in BAFF-R-positive CLL cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1181-7

Convergent potency of internalized gelonin immunotoxins across varied cell lines, antigens, and targeting moieties

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1181-7

Antibody engineering for therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1181-7

Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR Nanobodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1181-7

Ribosome display: an in vitro method for selection and evolution of antibodies from libraries

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1181-7

Expression of an oncogenic mutant EGF receptor markedly increases the sensitivity of cells to an EGF-receptor-specific antibody-toxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1181-7

Antibody targeted drugs as cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1181-7

Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1181-7

Anti-glioblastoma effect of a recombinant bispecific cytotoxin cotargeting human IL-13 and EGF receptors in a mouse xenograft model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1181-7

In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1181-7

The recombinant anti-EGF receptor immunotoxin 425(scFv)-ETA' suppresses growth of a highly metastatic pancreatic carcinoma cell line.

21 January 2018

1 reference

12 December 2020

Gelonin, a new inhibitor of protein synthesis, nontoxic to intact cells. Isolation, characterization, and preparation of cytotoxic complexes with concanavalin A

1 reference

12 December 2020

Photochemical internalisation increases the cytotoxic effect of the immunotoxin MOC31-gelonin

1 reference

12 December 2020

Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy

1 reference

12 December 2020

Recombinant anti-EGFR immunotoxin 425(scFv)-ETA' demonstrates anti-tumor activity against disseminated human pancreatic cancer in nude mice.

1 reference

12 December 2020

Single chain antibody fragments for ocular use produced at high levels in a commercial wheat variety

1 reference

12 December 2020

Cetuximab in advanced non-small cell lung cancer

1 reference

12 December 2020

Design, expression, purification, and characterization, in vitro and in vivo, of an antimelanoma single-chain Fv antibody fused to the toxin gelonin

1 reference

12 December 2020

Immunotoxins containing Pseudomonas exotoxin A: a short history

1 reference

12 December 2020

Genetic engineering of an immunotoxin to eliminate pulmonary vascular leak in mice

1 reference

12 December 2020

Decreases in levels of serum fibronectin predict the severity of vascular leak syndrome in patients treated with ricin A chain-containing immunotoxins

1 reference

12 December 2020

Characterization of vascular leak syndrome induced by the toxin component of Pseudomonas exotoxin-based immunotoxins and its potential inhibition with nonsteroidal anti-inflammatory drugs

1 reference

12 December 2020

10.1007/S00432-012-1181-7

Identifiers

DOI

1 reference

11 September 2017

1 reference